Skip to main content

Table 2 Prevalence of mutations in molecular markers of day 0 samples from day 3 positive and negative patients after treatment with artemether-lumefantrine

From: Efficacy of artemether-lumefantrine for treating uncomplicated Plasmodium falciparum cases and molecular surveillance of drug resistance genes in Western Myanmar

Gene

Mutation

n (%) of isolates

Pa

Day 3 positive, n = 4

Day 3 negative, n = 26

Total, n = 30

pfk13

K189T

0 (0.0)

3 (11.5)

3 (10.0)

1.000

NN insertion

4 (100.0)

13 (50.0)

17 (56.7)

0.113

pfcrt

K76T

4 (100.0)

26 (100.0)

30 (100.0)

1.000

A220S

4 (100.0)

26 (100.0)

30 (100.0)

1.000

Pfmdr1

Y184F

1 (25.0)

6 (23.1)

7 (23.3)

1.000

G968A

0 (0.0)

1 (3.8)

1 (3.3)

1.000

pfdhps

S436A

4 (100.0)

20 (76.9)

24 (80.0)

0.557

A437G

4 (100.0)

26 (100.0)

30 (100.0)

1.000

K540E

4 (100.0)

23 (88.5)

27 (90.0)

1.000

A581G

0 (0.0)

1 (3.8)

1 (3.3)

1.000

pfdhfr

N51I

4 (100.0)

20 (76.9)

24 (80.0)

0.557

C59R

4 (100.0)

26 (100.0)

30 (100.0)

1.000

S108N

4 (100.0)

26 (100.0)

30 (100.0)

1.000

I164L

3 (75.0)

19 (73.1)

22 (73.3)

1.000

  1. aComparison between the two groups by Fisher’s exact test. Sequences with mixed types were excluded for single mutation analysis